GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 - 7.
The EUROGIN congress, which gathers scientists, clinicians and gynecologists, aims at providing an overview of current scientific advances in the field of cervical cancer and other diseases related to Human Papillomavirus (HPV) infection.
On the spotlight at EUROGIN 2015 will be ProCervix, Genticel's most advanced candidate therapeutic vaccine, with two oral presentations on its continuing clinical development. As a reminder, ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. Both presentations, together, will provide further analysis of ProCervix's phase 1 data as well as expand on the rationale that led Genticel to embark on the phase 2 trial in early 2014. Dr Pierre Van Damme, professor in Vaccinology, Director of the Vaccine and Infectious Disease Institute of the University of Antwerp, Belgium, and investigator in both the phase 1 and phase 2 studies with ProCervix said, "I am very satisfied to see this innovative therapeutic vaccine progressing seamlessly in the ongoing phase II clinical trial."
A preclinical study on Vaxiclase will also be presented. Vaxiclase is Genticel's technology platform that is ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. Specifically, Genticel will provide the pharmacological proof of concept of simultaneous delivery of multiple antigens of several oncogenic HPV types using the Vaxiclase technology. This is a necessary step in establishing the full preclinical proof of concept for Multivalent HPV, Genticel's second therapeutic vaccine candidate targeting six oncogenic HPV strains.
Genticel will also be present on the exhibitor floor at booth 11.
EUROGIN Sessions featuring ProCervix and Vaxiclase
OC 6 - Vaccine 3 (New developments)
05 Feb 2015 | 8.15 - 9.45 | Auditorium 3 | FIBES II
SS 1 - Immunotherapy of HPV-associated diseases
05 Feb 2015 | 14.45 - 16.15 | Auditorium 3 | FIBES II
SS 2 - New challenges facing HPV 16 & 18 infection
05 Feb 2015 | 16.40 - 18.00 | Auditorium 3 | FIBES II
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.
Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18.
Genticel is based in Paris and Toulouse and was awarded "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark in 2014.
Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.
For more information, please visit www.genticel.com
The company has also established Vaxiclase, a technology platform ideally adapted for use in immunotherapies against multiple infectious or cancerous diseases. This platform is already being used by Genticel to develop a second therapeutic HPV vaccine candidate, now in its preclinical stage. This drug candidate targets six of the most pertinent HPV strains that cause approximately 85% of all cervical cancers world-wide.
About the EUROGIN 2015 Congress
The EUROGIN 2015 Congress aims at developing a full review of current scientific developments in the field of cervical cancer and human papillomavirus related diseases, raising the public health profile and increasing the need for responsible health services in this area. The event endeavors to translate scientific and evidence-based research into clinical practice while highlighting the following aspects:
- Recent advances and updated scientific insights in HPV screening, testing and management
- The impact of HPV and associated cancers on public health
- Strategies to prevent and treat HPV related diseases
- Exchanging information on early detection, new diagnostic and therapeutic procedures and prevention strategies including screening and HPV vaccination
Speakers include international leaders from academic, government and private organizations, representatives of medical and scientific societies, as well as women's health associations who will discuss and exchange ideas on issues relevant to both individuals and public health.
|CONTACT GENTICEL||USA Investor Contact||INVESTOR CONTACT||PRESS CONTACT|
Chief Executive Officer
Tel.: +1 (212) 915 2577
Tel.: +33 (0)1 53 67 36 77
Tel.: +33 (0)1 53 67 36 90
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|GENTICEL||Euronext Paris||2.82 (c)||-13.23%||1 958 454|